LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D/R3

Clinical trials for LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D/R3 explained in plain language.

Never miss a new study

Get alerted when new LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D/R3 trials appear

Sign up with your email to follow new studies for LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D/R3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Terminated 1

Gene therapy trial for rare muscle disease halted after early phase

Disease control Terminated

This early-stage study aimed to test the safety of a single-dose gene therapy called SRP-9004 for a rare, inherited muscle-wasting disorder. It involved a small group of participants, some who could walk and some who could not, to see if the treatment was safe and if it could inc…

Matched conditions: LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D/R3

Phase: PHASE1 • Sponsor: Sarepta Therapeutics, Inc. • Aim: Disease control

Last updated Mar 30, 2026 14:33 UTC

LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D/R3

Get alerted when new LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2D/R3 trials appear

Gene therapy trial for rare muscle disease halted after early phase